Showing results (271-280 of 292) with videos related to
Sort By:
Pageof 30
Frontiers in Pharmacology|October 3, 2022
How to balance valuable innovation with affordable access to medicines in Belgium?Steven Simoens, Khadidja Abdallah, Liese Barbier, et al.Drugs|June 4, 2020
Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory DiseasesHoUng Kim, Rieke Alten, Luisa Avedano, et al.Drugs|February 1, 2020
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory DiseasesHoUng Kim, Rieke Alten, Luisa Avedano, et al.Frontiers in Pharmacology|December 19, 2019
Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method StudyEline van Overbeeke, Rosanne Janssens, Chiara Whichello, et al.Frontiers in Pharmacology|October 18, 2019
Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the USChiara Whichello, Eline van Overbeeke, Rosanne Janssens, et al.Human Reproduction (Oxford, England)|March 17, 2012
The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centresSteven Simoens, Gerard Dunselman, Carmen Dirksen, et al.The Patient|June 22, 2019
Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USARosanne Janssens, Selena Russo, Eline van Overbeeke, et al.Journal of Market Access & Health Policy|March 28, 2024
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and CollaboratorsThomas Desmet, Elaine Julian, Walter Van Dyck, et al.Journal of Market Access & Health Policy|June 7, 2023
The role of stakeholder involvement in the evolving EU HTA process: Lauren Van Haesendonck, Jörg Ruof, Thomas Desmet, et al.Frontiers in Pharmacology|September 11, 2023
An international comparative analysis and roadmap to sustainable biosimilar marketsKhalid A Alnaqbi, Agnès Bellanger, Alex Brill, et al.Pageof 30